BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Holdings Decreased by Toronto Dominion Bank

Toronto Dominion Bank trimmed its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 95.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 19,754 shares of the biotechnology company’s stock after selling 416,497 shares during the period. Toronto Dominion Bank’s holdings in BioMarin Pharmaceutical were worth $1,725,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Stratos Wealth Partners LTD. lifted its position in shares of BioMarin Pharmaceutical by 2.1% in the fourth quarter. Stratos Wealth Partners LTD. now owns 5,709 shares of the biotechnology company’s stock worth $550,000 after purchasing an additional 115 shares in the last quarter. Envestnet Portfolio Solutions Inc. lifted its position in BioMarin Pharmaceutical by 1.2% in the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 10,668 shares of the biotechnology company’s stock worth $932,000 after buying an additional 130 shares in the last quarter. First Horizon Advisors Inc. lifted its position in BioMarin Pharmaceutical by 33.3% in the 4th quarter. First Horizon Advisors Inc. now owns 576 shares of the biotechnology company’s stock worth $56,000 after buying an additional 144 shares in the last quarter. Atria Wealth Solutions Inc. boosted its stake in shares of BioMarin Pharmaceutical by 1.6% during the 4th quarter. Atria Wealth Solutions Inc. now owns 9,729 shares of the biotechnology company’s stock valued at $938,000 after buying an additional 153 shares during the period. Finally, IFM Investors Pty Ltd grew its holdings in shares of BioMarin Pharmaceutical by 0.4% during the 1st quarter. IFM Investors Pty Ltd now owns 38,328 shares of the biotechnology company’s stock valued at $3,348,000 after acquiring an additional 158 shares in the last quarter. 98.71% of the stock is owned by hedge funds and other institutional investors.

BioMarin Pharmaceutical Trading Down 1.2 %

BioMarin Pharmaceutical stock opened at $84.59 on Friday. BioMarin Pharmaceutical Inc. has a 52 week low of $73.68 and a 52 week high of $99.56. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.70 and a current ratio of 2.74. The firm has a market capitalization of $16.06 billion, a PE ratio of 79.06, a PEG ratio of 1.20 and a beta of 0.32. The business’s 50-day simple moving average is $81.75 and its 200-day simple moving average is $85.47.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings results on Wednesday, April 24th. The biotechnology company reported $0.49 EPS for the quarter, topping the consensus estimate of $0.37 by $0.12. BioMarin Pharmaceutical had a return on equity of 5.34% and a net margin of 8.31%. The company had revenue of $648.83 million for the quarter, compared to the consensus estimate of $649.75 million. Equities research analysts forecast that BioMarin Pharmaceutical Inc. will post 2 earnings per share for the current year.

Analyst Ratings Changes

BMRN has been the subject of a number of research reports. Citigroup reduced their price objective on BioMarin Pharmaceutical from $94.00 to $91.00 and set a “neutral” rating for the company in a research report on Thursday, April 25th. Canaccord Genuity Group reiterated a “hold” rating and set a $89.00 price target on shares of BioMarin Pharmaceutical in a report on Thursday. Wells Fargo & Company boosted their price target on BioMarin Pharmaceutical from $110.00 to $115.00 and gave the company an “overweight” rating in a research note on Thursday, June 27th. Morgan Stanley cut their price objective on shares of BioMarin Pharmaceutical from $115.00 to $112.00 and set an “overweight” rating on the stock in a research report on Friday, April 26th. Finally, Scotiabank lifted their target price on shares of BioMarin Pharmaceutical from $83.00 to $85.00 and gave the company a “sector perform” rating in a research note on Thursday, April 25th. Ten equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, BioMarin Pharmaceutical has an average rating of “Moderate Buy” and an average target price of $102.00.

Insider Activity

In related news, EVP George Eric Davis sold 40,850 shares of the company’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $74.51, for a total transaction of $3,043,733.50. Following the completion of the transaction, the executive vice president now directly owns 56,157 shares in the company, valued at approximately $4,184,258.07. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other BioMarin Pharmaceutical news, CFO Brian Mueller sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $75.19, for a total value of $375,950.00. Following the completion of the transaction, the chief financial officer now owns 72,159 shares of the company’s stock, valued at approximately $5,425,635.21. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP George Eric Davis sold 40,850 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $74.51, for a total value of $3,043,733.50. Following the sale, the executive vice president now directly owns 56,157 shares in the company, valued at approximately $4,184,258.07. The disclosure for this sale can be found here. Over the last three months, insiders sold 67,700 shares of company stock valued at $5,209,352. 1.85% of the stock is owned by company insiders.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.